Trial: 201807170

A Double Blind, Placebo Controlled Dose Range Finding Study to Assess the Safety, Pharmacokinetics, and Efficacy of Tempol for the Reduction of Severe Mucositis in Head and Neck Cancer Patients Undergoing Combined Radio- and Chemotherapy

Phase

II

Principal Investigator

Adkins, Douglas

Disease Site

Ill-Defined Sites; Lip, Oral Cavity and Pharynx

Learn more about this study at: clinicaltrials.gov